老年急性缺血性脑卒中患者早期辅助服用心脑舒通胶囊的临床疗效观察

目的 探讨早期辅助服用心脑舒通胶囊对老年急性缺血性脑卒中患者的抗脑缺血作用及对神经功能缺损的影响.方法 80例老年急性缺血性脑卒中患者按随机数字表法分为治疗组和对照组,每组各40例;在基础治疗的基础上,治疗组加用心脑舒通胶囊3粒口服,每日3次,疗程30 d;治疗前,治疗后15 d、30 d对两组进行欧洲卒中量表(ESS)评分和临床疗效评价.结果 治疗组ESS评分在治疗前,治疗后15 d、30 d分别为56.24±10.48、65.41±11.82、72.52±13.21,对照组ESS评分在相应时间段分别为57.73±9.85、59.52±10.13、62.48±12.73,治疗后15 d、30 d两组ESS评分比较差异均有统计学意义(P＜0.05).两组临床疗效比较差异有统计学意义(Z=-2.813,P=.005).结论 心脑舒通胶囊具有一定的抗脑缺血作用,并能改善脑卒中后患者的神经功能缺损.

Therapeutic efficacy of auxiliary early-adoption of Xinnao shutong capsules in senile patients with acute ischemic stroke

Objective To study the efficacy of auxiliary early-adoption of Xinnao shutong capsules on anti-cerebral ischemia and neurological protection in senile patients with acute ischemic stroke. Methods Eighty senile patients with acute ischemic stroke were equally randomized into control group and treatment group. Conventional treatment was given to the control group; besides the conventional treatment, the Xinnao shutong capsules at a dosage of 3 pills and three- times daily for 30 d was given to the treatment group. The clinical efficacy and European stroke scale (ESS) scores were recorded and evaluated. Results The ESS scores in the treatment and control groups before the treatment were (56.24±10.48) and (57.73±9.85), respectively. The ESS scores in the treatment group on the 15th and 30th d of treatment (65.41±11.82, 72.52±13.21) was significantly improved as compared with those in the control group (59.52±10.13, 62.48±12.73) (P＜0.05). Significant differences on the clinical efficacy were noted between the 2 groups (Z=-2.813, P=0.005). Conclusion Xinnao shutong capsules have the effect of anti-cerebral ischemia and decreasing the neurological deficits in patients with acute ischemic stroke.